Irreversible electroporation for the management of pancreatic cancer: Current data and future directions

doi:10.3748/wjg.v29.i2.223

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7273)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

378

WORD

HTML

3684

Figures (1-1)

610

Tables (1-2)

772

Sum=5513

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

439

Download

1321

Sum=1760

Jan 14, 2023 (publication date) through Oct 31, 2025

Times Cited of This Article

Times Cited (13)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Opinion Review

World J Gastroenterol. Jan 14, 2023; 29(2): 223-231
Published online Jan 14, 2023. doi: 10.3748/wjg.v29.i2.223

Open in New Tab Full Size Figure Download Figure

Figure 1 Pancreatic cancer treated with percutaneous irreversible electroporation. A: Axial computed tomography (CT) showing a lesion (arrow) in the body of the pancreas consistent with ductal adenocarcinoma previously treated with chemo and radiation therapy; B: Positron emission tomography (PET)-CT scan showed the residual active part of the lesion (arrow); C: CT coronal view with 4 parallel electrodes positioned within the lesion; D and E: 3-mo follow-up CT (D) and PET-CT (E) showing complete ablation of the tumor with photopenic area in the site of ablation (arrow).

Citation: Spiliopoulos S, Reppas L, Filippiadis D, Delvecchio A, Conticchio M, Memeo R, Inchingolo R. Irreversible electroporation for the management of pancreatic cancer: Current data and future directions. World J Gastroenterol 2023; 29(2): 223-231
URL: https://www.wjgnet.com/1007-9327/full/v29/i2/223.htm
DOI: https://dx.doi.org/10.3748/wjg.v29.i2.223